Table 2 Univariate analysis between those who received neoadjuvant therapy and those who did not
From: Locally advanced thymoma; does neoadjuvant chemotherapy make a difference?
Variable | Total N = 23 | Neoadjuvant | p Value | |
|---|---|---|---|---|
Yes N = 12 | No N = 11 | |||
Gender | ||||
Female | 5 | 3 (60%) | 2 (40%) | 0.99 |
Male | 18 | 9 (50%) | 9 (50%) | |
Negative resection margin | ||||
No | 5 | 4 (80%) | 1 (20%) | 0.317 |
Yes | 18 | 8 (44%) | 10 (56%) | |
Smoking | ||||
Missing | 1 | 0 | 1 | 0.99 |
Ex-smoker | 4 | 2 (50%) | 2 (50%) | |
No | 12 | 7 (58%) | 5 (42%) | |
Yes | 6 | 3 (50%) | 3 (50%) | |
Stage | ||||
I | 3 | 1 (33%) | 2 (67%) | 0.013 |
II | 5 | 0 | 5 (100%) | |
III | 3 | 2 (67%) | 1 (33%) | |
IV | 12 | 9 (75%) | 3 (25%) | |
Histology | ||||
A | 1 | 0 | 1 (9.1%) | 0.99 |
AB | 4 | 2(16.7%) | 2 (18.2%) | |
BI | 1 | 0 | 1 (100%) | |
BII | 8 | 4 (50%) | 4 (50%) | |
BIII | 9 | 6 (67%) | 3 (33%) | |
Surgical approach | ||||
Open | 12 | 10 (83%) | 2 (17%) | 0.002 |
VATS | 11 | 2 (18%) | 9 (82%) | |
Adjuvant therapy | ||||
No | 8 | 5 (63%) | 3 (38%) | 0.667 |
Yes | 15 | 7 (47%) | 8 (53%) | |
Complications | ||||
No | 17 | 8 (47%) | 9 (53%) | 0.640 |
Yes | 6 | 4 (67%) | 2 (33%) | |
Lymphovascular invasion | ||||
Missing | 7 | 4 (57%) | 3 (43%) | 0.282 |
No | 11 | 4 (36%) | 7 (64%) | |
Yes | 5 | 4 (80%) | 1 (20%) | |
Myasthenia gravis diagnosis | ||||
No | 18 | 11 (61%) | 7 (39%) | 0.155 |
Yes | 5 | 1 (20%) | 4 (80%) | |
Current status | ||||
Alive | 22 | 11 (50%) | 11 (50%) | 0.99 |
Dead | 1 | 1 (100%) | 0 | |
Recurrence | ||||
No | 18 | 8 (44%) | 10 (56%) | 0.317 |
Yes | 5 | 4 (80%) | 1 (20%) | |
Cystic component | ||||
Missing | 3 | 2 (67%) | 1 (33%) | 0.474 |
No | 18 | 10 (56%) | 8 (44%) | |
Yes | 2 | 0 | 2 (100%) | |